RESEARCH DATABASE

InBody Scholar

InBody continues to work closely with academic researchers on a global scale to develop more in-depth clinical applications of body composition.
With our long history in the industry, we provide more than 6,000 research and publications.
Research title with ★ indicates InBody recommended paper.

The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a

Endocrinology
Author
Kato K et al.
Used Parameters : TBW, SLM, BFM
Publication Year : 2017
Country : Japan
Journal : Expert Opinion on Pharmacotherapy
Background: This study examined the effects of short-term administration of the sodium glucose cotransporter 2 (SGLT-2) inhibitor, dapagliflozin, on visceral fat area (VFA) in Japanese patients with type 2 diabetes. Research design and methods: In this randomized, crossover, controlled clinical trial, overweight patients with type 2 diabetes were randomized to treatment with 5 mg dapagliflozin for the first (n= 27) or second 12-week study period (n= 29). The parameters evaluated at baseline and after 12 and 24 weeks included blood …
Full text
List
Powered by KBoard